GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » 5-Day RSI

Paion Ag (Paion Ag) 5-Day RSI : 1.69 (As of May. 03, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-03), Paion Ag's 5-Day RSI is 1.69.

The industry rank for Paion Ag's 5-Day RSI or its related term are showing as below:

PAIOF's 5-Day RSI is ranked better than
98.76% of 1133 companies
in the Drug Manufacturers industry
Industry Median: 56.45 vs PAIOF: 1.69

Competitive Comparison of Paion Ag's 5-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion Ag's 5-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Paion Ag's 5-Day RSI falls into.



Paion Ag  (OTCPK:PAIOF) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion Ag  (OTCPK:PAIOF) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Paion Ag 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Paion Ag's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.